Suven Pharmaceuticals reported 20.09% fall in net profit to Rs 109.46 crore on 11% decline in net sales to Rs 348.49 crore in Q3 FY23 over Q3 FY22.
Profit before tax shed by nearly 20% year on year to Rs 147.28 crore in the quarter ended 31 December 2022.EBITDA de-grew 18.29% to Rs 159.58 crore in the third quarter from Rs 195.30 crore reported in the same period last year. EBITDA margin slipped to 44.20% in Q3 FY23 as against 48.72% in Q3 FY22.
Total expenses rose marginally to Rs 213.71 crore while cost of materials consumed increased by 14.09% to Rs 135.16 crore during the period under review.
On consolidate basis, the pharma company's net profit slid 32.7% to Rs 107.72 crore on 9.66% decrease in net sales to Rs 353.77 crore in Q3 FY23 over Q3 FY22.
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of global pharma industry.
The scrip rose 1.11% to Rs 490.05 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app